Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to three new employees to purchase an aggregate of 26,200 shares of the Company's common stock, effective as of January 2, 2025. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
旧金山，2025年1月3日（全球新闻通讯社）—— Olema Pharmaceuticals, Inc.（"Olema"或"Olema Oncology"，纳斯达克：OLMA）是一家临床阶段生物制药公司，专注于针对乳腺癌及其他疾病的靶向疗法的发现、开发和商业化。今天，公司宣布已经向三名新员工授予了期权，允许他们总共购买26,200股公司的普通股，自2025年1月2日起生效。这些奖励获得了Olema董事会的薪酬委员会的批准，并根据公司的2022年诱导计划授予，作为新员工入职Olema的诱因，符合纳斯达克上市规则5635(c)(4)。
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of $5.57 per share, equal to the last reported sale price of the Company's common stock as reported by Nasdaq on January 2, 2025. The stock options are subject to the terms of the Olema Pharmaceuticals, Inc., 2022 Inducement Plan.
这些期权在四年内逐步归属，其中25%在该员工的归属开始日期的第一周年归属，剩余部分在接下来的三年内按36个相等的月度分期归属，前提是该员工在这些归属日期时持续受雇于Olema。这些期权的期限为10年，行使价格为每股5.57美元，等于2025年1月2日纳斯达克所报告的公司普通股的最后成交价格。这些期权受Olema Pharmaceuticals, Inc. 2022年诱导计划的条款约束。
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
Olema根据纳斯达克上市规则5635(c)(4)提供此信息。
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at .
关于 Olema 肿瘤学
Olema肿瘤学是一家临床阶段生物制药公司，致力于改变治疗标准，提高乳腺癌患者及其他患者的治疗效果。Olema正在利用我们对内分泌驱动癌症、核受体和获得性支撑位机制的深入理解，推进一系列新疗法。我们的领先产品候选药物palazestrant（OP-1250）是一种专有的、可口服的完全雌激素受体拮抗剂（CERAN）和选择性雌激素受体降解剂（SERD），目前正在进行名为OPERA-01的第三阶段临床试验。此外，Olema还在开发一种有效的KAT6抑制剂（OP-3136）。Olema总部位于旧金山，在马萨诸塞州的剑桥有业务。欲了解更多信息，请访问我们。
Media and Investor Relations Contact
Courtney O'Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
媒体和投资者关系联系
考特尼·奥科内克
企业通信副总裁
Olema Oncology
media@olema.com
